PortalPublikationenMyeloid growth factors in acute myeloid leukemia: systematic...

Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials

Standard

Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. / Heuser, Michael; Zapf, Antonia; Morgan, Michael; Krauter, Jürgen; Ganser, Arnold.

in: ANN HEMATOL, Jahrgang 90, Nr. 3, 03.2011, S. 273-281.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Heuser, M, Zapf, A, Morgan, M, Krauter, J & Ganser, A 2011, 'Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials', ANN HEMATOL, Jg. 90, Nr. 3, S. 273-281. https://doi.org/10.1007/s00277-010-1069-z

APA

Heuser, M., Zapf, A., Morgan, M., Krauter, J., & Ganser, A. (2011). Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. ANN HEMATOL, 90(3), 273-281. https://doi.org/10.1007/s00277-010-1069-z

Vancouver

Heuser M, Zapf A, Morgan M, Krauter J, Ganser A. Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. ANN HEMATOL. 2011 Mär;90(3):273-281. https://doi.org/10.1007/s00277-010-1069-z

Bibtex

@article{1ab519e13a6e4cbeb596810538b74ea0,
title = "Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials",
abstract = "Randomized controlled trials (RCT) investigating administration of colony-stimulating factors (CSF) during or after chemotherapy in acute myeloid leukemia (AML) patients have not been systematically reviewed. We performed a meta-analysis of all reported RCTs comparing prophylactic or concurrent use of CSFs in adult AML patients. Two reviewers extracted data independently. Summary estimates with 95% confidence intervals (CIs) were calculated using a fixed effects model. Fourteen RCTs (n = 4,069 patients) were identified investigating prophylactic CSF administration. Time to neutrophil recovery (>500/μl) was significantly reduced in the CSF group (-4.13 days; 95% CI, -4.23 to -4.04) as was the length of hospitalization (-2.06 days; 95% CI, -2.36 to -1.76). However, no significant reduction in infection-related mortality was observed in CSF-treated compared with control patients (odds ratio (OR) 0.94; 95% CI, 0.8 to 1.1). Prophylactic CSF administration did not impact complete remission (CR) rate or survival. Fourteen RCTs (n = 4,518 patients) were identified investigating administration of CSFs during chemotherapy. Summary estimates of CR, disease/event-free, or overall survival were not significantly different for CSF versus control patients. Prophylactic CSF administration reduces the time to neutrophil recovery and length of hospitalization, but has no impact on documented infections or outcome. Economic analyses of prophylactic CSF administration in AML patients are warranted.",
keywords = "Adult, Anti-Bacterial Agents, Antineoplastic Combined Chemotherapy Protocols, Bacterial Infections, Colony-Stimulating Factors, Humans, Length of Stay, Leukemia, Myeloid, Acute, Neutropenia, Randomized Controlled Trials as Topic, Remission Induction, Secondary Prevention, Survival Rate, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review",
author = "Michael Heuser and Antonia Zapf and Michael Morgan and J{\"u}rgen Krauter and Arnold Ganser",
year = "2011",
month = mar,
doi = "10.1007/s00277-010-1069-z",
language = "English",
volume = "90",
pages = "273--281",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials

AU - Heuser, Michael

AU - Zapf, Antonia

AU - Morgan, Michael

AU - Krauter, Jürgen

AU - Ganser, Arnold

PY - 2011/3

Y1 - 2011/3

N2 - Randomized controlled trials (RCT) investigating administration of colony-stimulating factors (CSF) during or after chemotherapy in acute myeloid leukemia (AML) patients have not been systematically reviewed. We performed a meta-analysis of all reported RCTs comparing prophylactic or concurrent use of CSFs in adult AML patients. Two reviewers extracted data independently. Summary estimates with 95% confidence intervals (CIs) were calculated using a fixed effects model. Fourteen RCTs (n = 4,069 patients) were identified investigating prophylactic CSF administration. Time to neutrophil recovery (>500/μl) was significantly reduced in the CSF group (-4.13 days; 95% CI, -4.23 to -4.04) as was the length of hospitalization (-2.06 days; 95% CI, -2.36 to -1.76). However, no significant reduction in infection-related mortality was observed in CSF-treated compared with control patients (odds ratio (OR) 0.94; 95% CI, 0.8 to 1.1). Prophylactic CSF administration did not impact complete remission (CR) rate or survival. Fourteen RCTs (n = 4,518 patients) were identified investigating administration of CSFs during chemotherapy. Summary estimates of CR, disease/event-free, or overall survival were not significantly different for CSF versus control patients. Prophylactic CSF administration reduces the time to neutrophil recovery and length of hospitalization, but has no impact on documented infections or outcome. Economic analyses of prophylactic CSF administration in AML patients are warranted.

AB - Randomized controlled trials (RCT) investigating administration of colony-stimulating factors (CSF) during or after chemotherapy in acute myeloid leukemia (AML) patients have not been systematically reviewed. We performed a meta-analysis of all reported RCTs comparing prophylactic or concurrent use of CSFs in adult AML patients. Two reviewers extracted data independently. Summary estimates with 95% confidence intervals (CIs) were calculated using a fixed effects model. Fourteen RCTs (n = 4,069 patients) were identified investigating prophylactic CSF administration. Time to neutrophil recovery (>500/μl) was significantly reduced in the CSF group (-4.13 days; 95% CI, -4.23 to -4.04) as was the length of hospitalization (-2.06 days; 95% CI, -2.36 to -1.76). However, no significant reduction in infection-related mortality was observed in CSF-treated compared with control patients (odds ratio (OR) 0.94; 95% CI, 0.8 to 1.1). Prophylactic CSF administration did not impact complete remission (CR) rate or survival. Fourteen RCTs (n = 4,518 patients) were identified investigating administration of CSFs during chemotherapy. Summary estimates of CR, disease/event-free, or overall survival were not significantly different for CSF versus control patients. Prophylactic CSF administration reduces the time to neutrophil recovery and length of hospitalization, but has no impact on documented infections or outcome. Economic analyses of prophylactic CSF administration in AML patients are warranted.

KW - Adult

KW - Anti-Bacterial Agents

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bacterial Infections

KW - Colony-Stimulating Factors

KW - Humans

KW - Length of Stay

KW - Leukemia, Myeloid, Acute

KW - Neutropenia

KW - Randomized Controlled Trials as Topic

KW - Remission Induction

KW - Secondary Prevention

KW - Survival Rate

KW - Journal Article

KW - Meta-Analysis

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1007/s00277-010-1069-z

DO - 10.1007/s00277-010-1069-z

M3 - SCORING: Review article

C2 - 20838825

VL - 90

SP - 273

EP - 281

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 3

ER -